anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hernia through Winslow's hiatus, known as Blandin's hernia, a rare but potentially life-threatening condition, represents a diagnostic and therapeutic challenge. This case report describes a successful laparoscopic approach to a cecum hernia through the foramen of Winslow in a 63-year-old female.
CASE PRESENTATION: The patient presented with 24 hours of abdominal pain and nausea. Abdominal CT scan revealed a herniated cecum and terminal ileum compressing the gastric chamber and portal vein, leading to periportal edema. Laparoscopic right colectomy was performed after successful colon content evacuation via the greater gastric curvature to facilitate reduction. This was done to aid in reduction, as there were indications of non-viability in the right colon. The procedure unfolded without complications. The patient developed postoperative abdominal collections requiring percutaneous drainage but recovered well and was discharged within two weeks.
CONCLUSION: This case highlights the value of laparoscopy in managing foramen of Winslow hernias, offering minimally invasive benefits. Early diagnosis through imaging tools like CT is crucial for prompt surgical intervention and preventing complications like intestinal ischemia or perforation.
PROBLEM TO BE SOLVED: To obtain an anticancer drug useful for preventing and treating hepatoma by including a geranylgeranylamine derivative. SOLUTION: This anticancer drug includes a derivative of the formula (R<1> and R<2> are each independently H, alkyl, etc.), e.g. geranylgeranylamine. The derivative is obtained by aminating geranylgeranly chloride by a conventional method. The derivative is useful as an anticancer agent having little side effect because it shows not a cytocidal effect on the first generation of a cultured liver cell prepared from a murine hepar but a tumor-specific cytocidal effect in a cell strain originating from human hepatoma and shows low toxicity in an acute toxicity test.
This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
A single-arm phase II clinical trial of a short-term modified fasting regimen (STMF) is proposed to be conducted in 100 patients with solid tumors who are candidates to receive active medical or radiotherapy treatment (or with medical treatment or radiotherapy already ongoing). Cancer treatment can be adjuvant or palliative. Patients with haematological tumors are also included. Enrolment is also foreseen for patients with haematological tumors who are not undergoing active treatment yet, but are followed with a watchful waiting approach (e.g. patients with low-risk B-CLL or low-risk follicular lymphoma). Finally, enrolment is also open to patients with relapsing forms of non-melanoma skin cancers (e.g. basalioma, epithelioma).

The primary endpoint of the study is to evaluate the effects of a STMF on the circulating levels of factors with pro- or anti-oncogenic activity (including insulin, IGF1, IGFBP1, IGFBP3 , leptin, adiponectin, IL-6, TNF-alpha, IL1beta), as well as the effect of STMF cycles on leukocyte subpopulations with a role in the control of tumor growth, such as regulatory T cells, the "myeloid-derived suppressor cells" (MDSC) as well as NK cells, and on stem cell pools (e.g. hematopoietic stem cells, endothelial stem cells, mesenchymal stem cells).

The STMF regimen that is applied is a 5-day low-calorie and low-protein diet. Patients undergo a medical exam/history collection and a nutritional assessment (body weight, handgrip strenght and bioimpedance measurement) at baseline and then at the visits that precede every cycle of STMF (i.e. once every three weeks or monthly, depending on the therapeutic regimen the patient is undergoing, and in any case no more frequently than once every three weeks - eg when combined with q21 chemotherapy regimens). Adverse events are recorded at each visit in accordance with NCI-CTCAE version 5.0. P
BACKGROUND: After receiving neoadjuvant chemoradiation, the number of examined lymph nodes in resectable gastroesophageal cancer (GEC) will decrease, this may not accurately determine the N staging. So our study evaluates the clinical significance of a new staging model based on the logarithmic odds of positive lymph nodes (LODDS) in patients with GEC after receiving neoadjuvant chemoradiation.
METHODS: A total of 1 130 patients with pathologically diagnosed GEC who received neoadjuvant chemoradiation from 2004 to 2019 included in the National Cancer Institute Surveillance, Epidemiology, and Results (SEER) database were selected for analysis. Lymph nodes were staged according to the AJCC TNM staging system (eighth edition) and LODDS. Patient prognosis across the two systems were evaluated by the Kaplan-Meier method, differences in node staging were evaluated by the Akaike information criterion and Bayesian information criterion. In addition, 914 patients from our center were externally validated.
RESULTS: Compared to the traditional TNM staging system, the new TLODDSM staging system was comprised of stage I, stage II, stage IIIA, stage IIIB, and stage IVA, and decision curve analysis showed that the new staging system had higher benefits for different decision thresholds than the old staging system. The Akaike information criterion and Bayesian information criterion of the new staging system was lower than those of the old staging system, indicating the sensitivity of the TLODDSM staging system for predicting the prognosis of patients was higher. In addition, stage-IIIB or -IVA patients in the new staging system benefited from adjuvant chemotherapy. The externally validated data from our center supported this conclusion.
CONCLUSIONS: Compared to the TNM staging system, the TLODDSM staging system has significant advantages in predicting prognosis of patients with GEC who have completed neoadjuvant chemoradiation, guiding the adjuvant chemotherapy for patients.
Scientific and technologic advances in medicine have resulted in the ability of the medical team to prolong life. One consequence of life-extending advancements in technology is the increasing numbers of patients requiring prolonged mechanical ventilation (PMV). Prolonged mechanical ventilation has been defined as the need for 21 days, of consecutive mechanical ventilation for six hours/day. The interaction of underlying diseases and prolong bedridden result in various complication in patients with PMV. Known complications can include: muscle weakness, atelectasis, and deconditioning. The muscle weakness occurred most commonly in patients with PMV and resulted in increasing time to wean successfully from mechanical ventilation, and longer stay in hospital. Exercise is effective in improving muscle strength and physical function in patients with heart failure and chronic obstructive pulmonary disease (COPD. However, patients with PMV may be too fragile to perform excise. Neuromuscular electrical stimulation (NMES) involves applying a series of stimuli to skeletal muscle, primarily to trigger muscle contraction, and it can be used for the recovery of muscle mass and muscle strength following prolonged immobilization. NMES also improve microcirculation and systemic circulation in patients with cardiopulmonary diseases. In addition, the application of NMES increases oxygen consumption of whole body and elicits physiologic effects that are similar to aerobic exercise. However, the effects of NMES on the PMV population remain unclear. Near-infrared spectroscopy (NIRS) is a recently developed noninvasive method of measuring tissue oxygenation, blood flow, and local tissue metabolism. NIRS combined with a vascular occlusion test is proposed as a tool to assess the microvascular response. Indirect calorimetry (IC) uses the method of breath-bybreath monitoring by pneumotachography to measure oxygen consumption (VO2) and carbon dioxide production (VCO2).

The purposes of this study:

1. to examine the acute effects of NMES on the microcirculation, physiologic response and metabolic demand in patients with PMV.
2. to investigate the training effects of NMES on microcirculation, muscle strength and weaning outcomes in patients with PMV. METHODS: Subjects who have been on ventilator for\>= 21 days are recruited form respiratory care center (RCC) and are randomly assigned into NMES (n=20) or control group (n=20).The NMES group receive daily NMES for 30 min/session for 10 days. The assessment of muscle strength and weaning profile were performed before and after intervention. During the first and the last NMES session, the status of microcirculation and local muscle tissue oxygenation will be measured by NIRS, and the metabolic status will be measured by IC. The mechanical ventilator weaning outcomes and length of stay in RCC will be recorded. The results of this study help us to confirm whether the application of NMES is beneficial in the improvement of muscle strength in patients with PMV, and to furtherly understand the mechanisms. The results may provide an alternative options for clinicians functional and hospitalization outcomes in patients with PMV.
PURPOSE: To assess diagnostic performance and reproducibility of reduced bowel wall enhancement evaluated by quantitative methods using CT to identify bowel necrosis among closed-loop small bowel obstruction (CL-SBO) patients.
METHODS: This retrospective single-center study included patients who diagnosed with CL-SBO caused by adhesion or internal hernia during January 2016 and May 2022. Patients were divided into necrotic group (n = 41) and non-necrotic group (n = 67) according to surgical exploration and postoperative pathology. Two doctors independently measured the attenuation of bowel wall and consensus was reached through panel discussion with a third gastrointestinal radiologist. Reduced bowel wall enhancement was assessed by four quantitative methods. Univariate analyses were used to evaluate the association between each method and bowel necrosis, and kappa/intraclass correlation coefficient values were used to assess interobserver agreement. Diagnostic performance parameters were calculated for each method.
RESULTS: Reduced bowel wall enhancement in arterial phase (OR 8.98, P < 0.0001), reduced bowel wall enhancement in portal phase (OR 16.84, P < 0.001), adjusted reduced bowel wall enhancement in arterial phase (OR 29.48, P < 0.001), adjusted reduced bowel wall enhancement in portal phase (OR 145.69, P < 0.001) were significantly associated with bowel necrosis. Adjusted reduced bowel wall enhancement in portal phase had the best diagnostic performance (AUC: 0.92; Youden index: 0.84; specificity: 94.03 %) and interobserver agreement (kappa value of 0.59-0.73) to predict bowel necrosis.
CONCLUSION: When assessing reduced bowel enhancement to predict bowel necrosis among CL-SBO patients, using unenhanced CT images and proximal dilated loop as standard references in portal phase is the most accurate quantitative method among those tested.
ABSTRACT OF THE DISCLOSURE          A multistage process for permanent hair shaping e.g. waving, in which prior to and/or after winding the hair on rollers it is treated with a liquid hair-keratin-reducins permanent shap-ing agent.  This liquid, weakly shaping-efficient permanent shap-ing agent can shape the hair in the region of the hair ends without damaging the hair ends during the reaction time.  A consistent, hair-keratin-reducing permanent shaping agent, which has a viscos-ity of 50 to 5000  mPa-s at 30°C, preferably 100 to 500  mPa.s, and a more intense shaping efficiency as compared with the liquid permanent shaping agent, is then applied.  The consistent perman-ent shaping agent shields the hair externally and thus prevents the admission of atmospheric oxygen on the one hand and the escape of a volatile alkalizing agent, as for example, ammonia, on the other.  Furthermore, a good shaping effect on the hairline is attained by the higher shaping efficiency of the consistent perman-ent shaping agent without the danger of overcurling the hair ends.          After an adequate reaction time the hair is rinsed and then treat-ed with a solution having an oxidizing effect.
The method of the invention in a telecommunication network for analyzing a Point-Of-Care, POC, test result comprises performing a Point-Of Care, POC, test and getting a test result. A signal from the test result is detected with a camera (2) in a telecommunication terminal and an image is obtained. The image is interpreted by an Artificial Neural Network, ANN, which makes a decision for an analysis of the image. The result of the analysis of the interpreted image is sent to a user interface of an end user. The system of the invention for analyzing the result of a point-of-care, POC, test comprises a test result of the point-of-care test, a terminal having a camera (2), and a user interface, and software for interpreting an image of the test result taken by the camera. The software uses an Artificial Neural Network for interpretation of the image and making an analysis.
Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
BACKGROUND: There is a paucity of data on whether parents' macrosomia (birthweight ≥4500 g) status influences the risk of macrosomia in the offspring. The role of maternal overweight in the generational effect of macrosomia is not known.
OBJECTIVE: To estimate the risk of macrosomia by parental birthweight at term and evaluate if this risk varied with maternal body mass index (BMI, kg/m2) early in pregnancy.
METHODS: We used data from the Medical Birth Registry of Norway on all singleton term births (37-42 gestational weeks) during 1967-2017. The primary exposure was parental macrosomia, and the outcome was macrosomia in the second generation. The secondary exposure was maternal BMI. We used binomial regression to calculate relative risk (RR) with a 95% confidence interval. We assessed potential unmeasured confounding and selection bias using a probabilistic bias analysis and performed analyses with and without imputation for variables with missing values.
RESULTS: The data included 647,957 singleton parent-offspring trios born at term. The prevalence of macrosomia was 3.2% (n = 41,396) in the parental generation and 4.0% (n = 25,673) in the offspring generation. Macrosomia in parents was associated with an increased risk of macrosomia in offspring, with the RR for both parents were born macrosomic being 6.53 (95% confidence interval [CI] 5.31, 8.05), only mother macrosomic 3.37 (95% CI 3.17, 3.57) and only father macrosomic RR 2.22 (95% CI 2.12, 2.33). These risks increased by maternal BMI in early pregnancy: if both parents were born macrosomic, 17% of infants were macrosomic among mothers with normal BMI. If both parents were macrosomic and the mothers were obese, 31% of offspring were macrosomic. Macrosomia-related adverse outcomes did not differ with parental macrosomia status.
CONCLUSIONS: Parents' weight at birth and maternal BMI appear to be strongly associated with macrosomia in the offspring delivered at term gestations.
A system supports creation and modification of a flexible and comprehensive location structure model able to track patients and identify suitable patient locations and location availability via a user friendly display interface. A method provides a user interface system facilitating movement of a patient in a healthcare enterprise. The method involves receiving search criteria information for use in identifying at least one suitable location for occupation by a patient. The search criteria is employed in searching a profile comprising information identifying a hierarchical organization of locations available to accommodate a patient for different purposes within a healthcare enterprise. The different purposes include, (a) for hosting a patient encounter with a healthcare enterprise involving patient and healthcare enterprise interaction, or (b) for accommodating a patient. The search result information is processed to provide location availability information suitable for presentation to a user via a displayed image in response to user command.
The invention discloses a scrub anti-allergy facial cleanser containing nanometer carbon crystal, and belongs to the field of daily chemical products. The facial cleanser is mainly prepared from the following raw materials in percent by weight: 0.5-1.5% of nanometer carbon crystal, 15-25% of aloe, 10-15% of osmanthus fragrans, 10-20% of calendula officinalis, 10-20% of apple flower, 0.5-1.0% of lavender essential oil, 2.0-3.0% of pelargonium-hortorum essential oil , and the balance being deionized water. The pH value of the facial cleanser is 6.0-6.5. The invention also discloses a preparation method for the scrub anti-allergy facial cleanser containing nanometer carbon crystal. The provided scrub anti-allergy facial cleanser containing nanometer carbon crystal employs nanometer carbon crystal subjected to surface functionalization processing as the raw material, original high strength and original high wear resistance of nanometer carbon crystal are kept, and also bacteria on skin surface are relatively effectively killed, and also the effects of removing free radicals, softening skin, resisting allergy, relieving skin and the like are realized. Anti-allergy substances adhered to skin possess skin-restoration composition substances, fast act on damages cells and restore skin.
This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study. Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
The submaximal heart and pulmonary evaluation (SHAPE™) test is an FDA approved cardiopulmonary exercise testing (CPET) system that provides a rapid and non-invasive way of characterizing cardiopulmonary reserve in a variety of medical conditions3,4. Traditional CPET testing has demonstrated predictive power in the assessment of postoperative mortality, hospital length of stay and other postoperative complications after lung resection, abdominal aortic aneurysm repair and liver transplants5-7. A unique advantage of SHAPE™ testing is that functional capacity variables are both obtained at rest and during sub-maximal exercise, potentially mimicking elicited conditions associated with surgical stress, as well as assist in determining the specific component of the physiological system under duress during testing (cardiac vs. pulmonary). Additionally, unlike conventional CPET, a maximum exercise effort is not required, making it an attractive option for patients with cardiopulmonary or musculoskeletal disorders and elderly patients who are unable to undergo the higher intensity exercise testing associated with traditional CPET. Finally, investigation of unique SHAPE™ variables (e.g. GXcap/Δend-tidal C02) which have been observed to be sensitive performance indicators for a variety of cardiovascular diseases such as heart failure with preserved ejection fraction, may prove more sensitive to traditional CPET variables or conventional echocardiography3.

This is a prospective, non-randomized feasibility study to evaluate the effectiveness of subject recruitment of an FDA-approved simplified cardiopulmonary exercise testing apparatus in adults \>60 years old prior to moderate to high-risk surgery. Pre-screened research subjects will be approached by telephone or in-person within the pre-surgical evaluation clinic prior to their surgery. We hypothesize that \>25% of eligible subjects will be recruited in the investigation. A single 35 minute in-person session will be performed where subjective metabolic equivalents will be assessed, and experimental session of the SHAPE™ medical system testing apparatus. Research subjects will then be released after survey. A follow-up telephone call at 24 hours will assess any adverse events related to the experimental session. For the period of 30 days after their scheduled surgery, minor and major postoperative complications will be extracted from the electronic medical record.
The present invention relates to pharmaceutical compositions comprising MBL and/or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200  mu g/ml protein containing material, wherein mannan binding lectin (MBL) and/or MBL variants constitutes at least 35% (w/w) of the total protein; or to compositions comprising at least 400  mu g/ml mannan binding lectin (MBL) and/or MBL variants. In addition the invention relates to pharmaceutical compositions comprising MBL and/or MBL variants and divalent cations. The invention also describes methods of preparing said compositions. <??>The pharmaceutical compositions according to the invention may for example be used in methods of treatment of a number of different clinical conditions including infections. Uses of the compositions for preparation of medicaments for treatment of a clinical condition are also described.
A heart monitor acquires signals representing a patient's heart characteristics. The signals are amplified without affecting the original signal characteristics. The heartbeat signals with unusual characteristics are then transmitted to a processing station. The station also contains, in a pattern recognition platform, the patient's previously generated heartbeat signals. The station compares the signals with unusual characteristics and the patient's previously generated signals and selects the previously generated signals closest in characteristics to the signals with the unusual characteristics. A comparator then compares the selected signals and database signals indicating different types of heart problems in third parties and selects the database signals closest in characteristics to the selected signals previously generated by the patient. Dependent upon the patient's heart problem severity indicated by the characteristics of the selected database signals), the monitor transmits the selected database signals to (a) the patient's doctor, (b) the patient's hospital or (c) an emergency number (e.g. 911).
The invention relates to an influenza virus strain with the preservation number of CGMCC No. 13784. The influenza virus strain inserts a 15nt sequence after the 78nt of the M2 gene coding region of the wild type influenza virus strain, and the sequence is shown as SEQ ID No. 2. The M gene sequence of the influenza virus strain is shown as SEQ ID No. 1. The invention also relates to application of the influenza virus strain in preparing a vaccine for preventing and/or treating influenza. The invention aims to obtain an influenza virus strain and apply the influenza virus strain to the production of vaccines.